Incruse Ellipta Approval History
Incruse Ellipta (umeclidinium) is an anticholinergic bronchodilator indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
Development History and FDA Approval Process for Incruse Ellipta
|May 1, 2014||FDA Approves Incruse Ellipta (umeclidinium) for the Treatment of COPD|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.